Antibiotic control of tumor-colonizing Salmonella enterica serovar Typhimurium.
dc.contributor.author | Crull, Katja | |
dc.contributor.author | Weiss, Siegfried | |
dc.date.accessioned | 2015-03-05T11:04:16Z | en |
dc.date.available | 2015-03-05T11:04:16Z | en |
dc.date.issued | 2011-11 | en |
dc.identifier.citation | Antibiotic control of tumor-colonizing Salmonella enterica serovar Typhimurium. 2011, 236 (11):1282-90 Exp. Biol. Med. (Maywood) | en |
dc.identifier.issn | 1535-3699 | en |
dc.identifier.pmid | 21987828 | en |
dc.identifier.doi | 10.1258/ebm.2011.011111 | en |
dc.identifier.uri | http://hdl.handle.net/10033/346200 | en |
dc.description.abstract | Systemic administration of Salmonella enterica serovar Typhimurium (S. typhimurium) into tumor-bearing mice results in preferential colonization of tumors and causes shrinkage and sometimes complete tumor clearance. However, in spite of these beneficial antitumor effects, the systemic administration of a bacterial pathogen raises serious safety concerns as well. Addressing those concerns, here, we demonstrate that tumor-colonizing Salmonella can be readily controlled by systemic administration of the antibiotic - ciprofloxacin. Treatment was most effective when started early postinfection. This was achieved at the expense of the efficacy of tumor therapy. In many of the mice treated in such a way, tumors re-grew again. Nevertheless, some mice were able to clear the tumor despite the start of antibiotic treatment only 24 h after the start of infection. Furthermore, we could demonstrate that such mice had elicited a specific antitumor immune response. Thus, S. typhimurium-mediated tumor therapy might be applied safely when combined with early antibiotic treatment. However, the therapeutic power of the bacteria needs to be enhanced in order to provide a more effective therapeutic tool. | |
dc.language.iso | en | en |
dc.subject.mesh | Animals | en |
dc.subject.mesh | Anti-Infective Agents | en |
dc.subject.mesh | Carcinoma | en |
dc.subject.mesh | Ciprofloxacin | en |
dc.subject.mesh | Colonic Neoplasms | en |
dc.subject.mesh | Disease Models, Animal | en |
dc.subject.mesh | Female | en |
dc.subject.mesh | Mice | en |
dc.subject.mesh | Mice, Inbred BALB C | en |
dc.subject.mesh | Salmonella Infections | en |
dc.subject.mesh | Salmonella typhimurium | en |
dc.title | Antibiotic control of tumor-colonizing Salmonella enterica serovar Typhimurium. | en |
dc.type | Article | en |
dc.identifier.journal | Experimental biology and medicine (Maywood, N.J.) | en |
refterms.dateFOA | 2018-06-13T03:47:31Z | |
html.description.abstract | Systemic administration of Salmonella enterica serovar Typhimurium (S. typhimurium) into tumor-bearing mice results in preferential colonization of tumors and causes shrinkage and sometimes complete tumor clearance. However, in spite of these beneficial antitumor effects, the systemic administration of a bacterial pathogen raises serious safety concerns as well. Addressing those concerns, here, we demonstrate that tumor-colonizing Salmonella can be readily controlled by systemic administration of the antibiotic - ciprofloxacin. Treatment was most effective when started early postinfection. This was achieved at the expense of the efficacy of tumor therapy. In many of the mice treated in such a way, tumors re-grew again. Nevertheless, some mice were able to clear the tumor despite the start of antibiotic treatment only 24 h after the start of infection. Furthermore, we could demonstrate that such mice had elicited a specific antitumor immune response. Thus, S. typhimurium-mediated tumor therapy might be applied safely when combined with early antibiotic treatment. However, the therapeutic power of the bacteria needs to be enhanced in order to provide a more effective therapeutic tool. |